Skip to main content
OpenTrials
Completed

NCT Number: NCT02691351

Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry Study

The better understanding of non-Hodgkin T-cell lymphoma is essential for establishing effective treatment strategy for non-Hodgkin T-cell lymphoma. Therefore, the data about conical features and treatment outcomes of each subtype should be accumulated to establish treatment strategy. However, the majority of previous data for non-Hodgkin T-cell lymphoma was from small case series of single institute. Furthermore, as novel drugs were developed for the treatment of relapsed or refractory T-cell lymphoma, the date from patients who were treated with those novel drugs are especially required because their outcomes may reflect the outcomes of currently available treatments. Thus, a multinational, multicenter prospective registry study is needed to provide information useful for establishing treatment strategies for T-cell lymphoma.

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Samsung Medical Center

Seoul, 135-710, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pathologically diagnosed Mature T-cell non-Hodgkin lymphoma based on the World Health Organization classification 2008
  • Newly diagnosed patients without a previous treatment history for T-cell lymphoma or relapsed/refractory T-cell lymphoma patients
  • Age ≥19 years
  • Written informed consent

Exclusion criteria

  • Hodgkin lymphoma
  • non-Hodgkin B-cell lymphoma
  • Immature non-Hodgkin T-cell lymphoma: Precursor T-lymphoblastic lymphoma/leukemia
  • Not understanding informed consent

Treatment and study plan

Prospective registry

Other

Survival and disease status follow-up at 1st primary treatment, 1st salvage treatment and 2nd salvage treatment

  • Regimen
  • Response Evaluation
  • SUSAR(Suspected, Unexpected, Serious, Adverse Reaction) collection

Primary outcomes

  1. Overall survival

    Time frame: 5 years

Secondary outcomes

  1. Overall response rate to primary treatment and salvage treatment

    Time frame: 5 years

  2. Progression-free survival

    Time frame: 5 years

Sponsors and collaborators

Lead sponsor

Samsung Medical Center

Other

Registry information

Important dates

Study start
2016
Primary completion
2020
Study completion
2020
First posted
Feb 25, 2016
Registry last updated
Sep 9, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.